ACTHREL
LOE ApproachingBLAINJECTIONINJECTABLEPriority Review
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
ACTHREL by Ferring Pharmaceuticals is clinical pharmacology pharmacodynamics in normal subjects, intravenous administration of corticorelin results in a rapid and sustained increase of plasma acth levels and a near parallel increase of plasma cortisol. First approved in 1996.
Drug data last refreshed 20h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics In normal subjects, intravenous administration of corticorelin results in a rapid and sustained increase of plasma ACTH levels and a near parallel increase of plasma cortisol. In addition, intravenous administration of corticorelin to normal subjects causes a…
Worked on ACTHREL at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.